Skip to main content
ADVANCED SEARCH
Log in

The AML expert series

This site and content is intended for healthcare professionals. Supported by an independent educational grant from Rigel.

The AML expert series: Innovations in molecular testing, emerging therapies & targeted treatments

Welcome to “The AML Expert Series”, a three-part video podcast series for hematologist-oncologists seeking to enhance their knowledge, skills, and practice in molecular testing, emerging therapies, and targeted treatments in relapsed/refractory (R/R) acute myeloid leukemia (AML). 

Professor Amer Zeidan, MBBS, MHS, hosts engaging discussions with each episode’s topic expert, to curate a series of diverse perspectives and deep insights that inform and inspire. Dive in to learn more about genetic testing and diagnostics, evidence-based regimens and guidelines, emerging targeted therapies, and personalized treatments in R/R AML. 

Hear directly from the experts on real-world experiences, actionable strategies, and practical advice for improving your patients care.

Episode 1

Unveiling the mysteries of molecular testing in AML: a guide for oncologists

  30 min

Prof. Amer Zeidan, MBBS, MHS | Dr. Sanam Loghavi, MD

Unlock effective strategies for implementing molecular testing and overcoming barriers in clinical practice.

Find out more

Episode 2

Advancing AML treatment: evidence-based regimens and guidelines for R/R AML management

  25 min

Prof. Amer Zeidan, MBBS, MHS | Dr. Eunice Wang, MD

Explore the latest evidence-based regimens and guideline updates for the clinical application of targeted therapy in R/R AML.

Find out more

Episode 3

Deep dive into targeted therapies: understanding IDH1-mutant AML treatments

  20 min

Prof. Amer Zeidan, MBBS, MHS | Prof. Courtney D. DiNardo, MD, MSCE 

Discover the mechanism of action, efficacy, and safety profiles of novel targeted therapies for IDH1-mutant R/R AML.   

Find out more

FACULTY INFORMATION

Prof. Amer Zeidan, MBBS, MHS

Yale School of Medicine
New Haven, CT, 
USA

Prof. Courtney D. DiNardo, MD, MSCE

MD Anderson Cancer Center
Houston, TX, 
USA

Dr. Sanam Loghavi, MD

MD Anderson Cancer Center
Houston, TX, 
USA

Dr. Eunice Wang, MD

Roswell Park Comprehensive Cancer Center
Buffalo, NY,
USA

LEARNING OBJECTIVES

Describe the various molecular testing methods and the common barriers to their implementation for identifying IDH1 mutations in AML

Evaluate evidence‐based regimens and guideline updates for the clinical application of IDH1‑targeted treatments

Describe the mechanisms of action, efficacy, and safety profiles of novel targeted therapies for IDH1‑mutant AML

TARGET AUDIENCE

This program is intended for healthcare professionals only, and is designed to meet the educational needs of oncologists/hematologists, pathologists, and the multidisciplinary team involved in the diagnosis, interpretation of test results, treatment, and management of patients with AML.

PRESSED FOR TIME?

Tune in to the audio version of this expert podcast on Spotify, Apple Podcasts, or your favorite podcast platform. Anytime, Anywhere!

IME@springer.com 
© 2025 Springer Healthcare LLC. Springer Health+ IME is part of Springer Nature. All rights reserved.

Image Credits